---
layout: default
title: Felodipine
description: "Felodipine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 7 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 70
evidence_level: L5
indication_count: 7
---

# Felodipine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>7</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Felodipine è—¥å¸«è©•ä¼°ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Felodipine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Felodipine æ˜¯éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯ç”¨æ–¼å¤šç¨®è‚ºé«˜å£“å’Œæƒ¡æ€§é«˜è¡€å£“ï¼Œé€™äº›é æ¸¬å…·æœ‰è—¥ç†å­¸åŸºç¤ä½†ç¼ºä¹å°ˆé–€çš„è‡¨åºŠè©¦é©—è­‰æ“šã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Felodipine (éæ´›åœ°å¹³) |
| DrugBank ID | DB01023 |
| å°ç£å•†å“å | éæ´›åœ°å¹³ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€å£“ã€å¿ƒçµç—› |
| é æ¸¬æ–°é©æ‡‰ç—‡ | pulmonary hypertension owing to lung disease and/or hypoxiaã€pulmonary hypertension with unclear multifactorial mechanismã€malignant renovascular hypertensionã€malignant hypertensive renal diseaseã€hypertensive disorderã€Braddock syndromeã€chronic pulmonary heart disease |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9991 (pulmonary hypertension) |
| è­‰æ“šç­‰ç´š | L4 (å‰è‡¨åºŠ) è‡³ L5 (åƒ…é æ¸¬) |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Felodipine ä½œç‚ºäºŒæ°«å¡å•¶é¡éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ï¼Œå…¶å°é æ¸¬é©æ‡‰ç—‡çš„æ½›åœ¨ç™‚æ•ˆæœ‰ä»¥ä¸‹è—¥ç†å­¸åŸºç¤ï¼š

1. **è¡€ç®¡æ“´å¼µä½œç”¨**ï¼šé˜»æ–· L-type éˆ£é›¢å­é€šé“ï¼Œå°è‡´å‹•è„ˆå¹³æ»‘è‚Œé¬†å¼›
2. **è‚ºè¡€ç®¡æ“´å¼µ**ï¼šç†è«–ä¸Šå¯é™ä½è‚ºè¡€ç®¡é˜»åŠ›
3. **è…è¡€ç®¡æ•ˆæ‡‰**ï¼šå¯æ”¹å–„è…è‡ŸçŒæµï¼Œå°æƒ¡æ€§é«˜è¡€å£“æ€§è…ç—…å¯èƒ½æœ‰ä¿è­·ä½œç”¨
4. **åŒé¡è—¥ç‰©ç¶“é©—**ï¼šå…¶ä»–éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘(å¦‚ nifedipine)å·²è¢«ç”¨æ–¼æŸäº›é¡å‹çš„è‚ºé«˜å£“

### é™åˆ¶å› ç´ 
- Felodipine å°å‘¨é‚Šè¡€ç®¡çš„é¸æ“‡æ€§é«˜æ–¼è‚ºè¡€ç®¡
- ç¾ä»£è‚ºé«˜å£“æ²»ç™‚ä¸»è¦ä½¿ç”¨å°ˆé–€çš„è‚ºè¡€ç®¡æ“´å¼µåŠ‘(å¦‚ sildenafil, bosentan)
- éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘åƒ…å°ç´„ 10% çš„è‚ºé«˜å£“æ‚£è€…æœ‰æ•ˆ

## è‡¨åºŠè©¦é©—è­‰æ“š

### ClinicalTrials.gov æœå°‹çµæœ

**æœªç™¼ç¾** Felodipine ç”¨æ–¼ä»¥ä¸‹é æ¸¬é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ï¼š
- è‚ºé«˜å£“(èˆ‡è‚ºç–¾ç—…/ç¼ºæ°§ç›¸é—œ)
- æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“
- æƒ¡æ€§é«˜è¡€å£“æ€§è…ç—…

**è­‰æ“šç­‰ç´šï¼šL5 (åƒ…é æ¸¬)**

## æ–‡ç»è­‰æ“š

### è‚ºé«˜å£“/ç¼ºæ°§ç›¸é—œ

PubMed æœå°‹ç™¼ç¾ä¸€äº›é–“æ¥ç›¸é—œçš„æ–‡ç»ï¼š

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | é—œéµç™¼ç¾ |
|------|------|----------|---------|
| 33862277 | 2021 | ç¶œè¿° | è¨è«–ç¼ºæ°§èˆ‡è…¦éƒ¨è€åŒ–çš„é—œä¿‚ï¼Œæœªç›´æ¥æ¶‰åŠ felodipine |
| 2164797 | 1990 | ç¶œè¿° | éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘åœ¨ç¼ºæ°§å¾Œè…¦ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ |

### æƒ¡æ€§é«˜è¡€å£“/è…è¡€ç®¡æ€§é«˜è¡€å£“

| æœå°‹çµæœ | èªªæ˜ |
|---------|------|
| è³‡æ–™æ”¶é›†æ™‚ç™¼ç”ŸéŒ¯èª¤ | ç£ç¢Ÿç©ºé–“ä¸è¶³å°è‡´éƒ¨åˆ†æ–‡ç»æœªèƒ½ä¸‹è¼‰ |

**æ–‡ç»è­‰æ“šä¸è¶³**ï¼Œéœ€è¦é€²ä¸€æ­¥æœå°‹ç›¸é—œç ”ç©¶ã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| ä¸»è¦è£½åŠ‘ | éæ´›åœ°å¹³ç·©é‡‹éŒ  |
| å¸¸è¦‹åŠ‘é‡ | 5mg, 10mg |
| æ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€å£“ã€å¿ƒçµç—› |

### ç›¸é—œè¤‡æ–¹è£½åŠ‘
- å« Felodipine + Enalapril çš„è¤‡æ–¹è£½åŠ‘ç”¨æ–¼é«˜è¡€å£“æ²»ç™‚
- ä¸å»ºè­°ä½œç‚ºèµ·å§‹æ²»ç™‚

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥é¢¨éšª
- **å‘¨é‚Šæ°´è…«**ï¼šæœ€å¸¸è¦‹å‰¯ä½œç”¨ï¼Œèˆ‡åŠ‘é‡ç›¸é—œ
- **é ­ç—›**ï¼šè¡€ç®¡æ“´å¼µç›¸é—œ
- **æ½®ç´…**ï¼šç´„ 10% æ‚£è€…
- **å¿ƒæ‚¸**ï¼šåå°„æ€§å¿ƒè·³åŠ é€Ÿ
- **ç‰™é½¦å¢ç”Ÿ**ï¼šé•·æœŸä½¿ç”¨å¯èƒ½ç™¼ç”Ÿ

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | æ©Ÿè½‰ | è‡¨åºŠæ„ç¾© |
|-------------|------|---------|
| CYP3A4 æŠ‘åˆ¶åŠ‘ | ä»£è¬æ¸›æ…¢ | è¡€å£“éåº¦é™ä½ |
| è‘¡è„æŸšæ± | CYP3A4 æŠ‘åˆ¶ | é¿å…ä½µç”¨ |
| Beta-blockers | å”åŒé™å£“ | å¯èƒ½éœ€è¦æ¸›é‡ |
| Digoxin | è¡€ä¸­æ¿ƒåº¦å‡é«˜ | ç›£æ¸¬ digoxin æ¿ƒåº¦ |

### ç‰¹æ®Šæ—ç¾¤
- **å­•å©¦**ï¼šC ç´šï¼Œä¸å»ºè­°ä½¿ç”¨
- **å“ºä¹³**ï¼šåˆ†æ³Œè‡³ä¹³æ±ï¼Œä¸å»ºè­°ä½¿ç”¨
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šéœ€æ¸›é‡
- **è€å¹´äºº**ï¼šå¯èƒ½éœ€è¼ƒä½èµ·å§‹åŠ‘é‡

### è‚ºé«˜å£“ç‰¹æ®Šè€ƒé‡
å¦‚ç”¨æ–¼è‚ºé«˜å£“ï¼Œéœ€æ³¨æ„ï¼š
- åƒ…å°è¡€ç®¡åæ‡‰æ€§é™½æ€§çš„æ‚£è€…æœ‰æ•ˆ
- éœ€åœ¨å°ˆæ¥­ä¸­å¿ƒé€²è¡Œæ€¥æ€§è¡€ç®¡åæ‡‰æ€§è©¦é©—
- å¯èƒ½å°è‡´å…¨èº«æ€§ä½è¡€å£“è€Œæƒ¡åŒ–å³å¿ƒåŠŸèƒ½

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechan...
- å»ºè­°ï¼šThe manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amount...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ç™‚æ•ˆ
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¡ Moderate
- Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also...

**Shock, Cardiogenic** ğŸŸ¢ Minor
- In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further dep...

**Coronary Artery Disease** ğŸŸ¢ Minor
- Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use o...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°
æ­¤é æ¸¬**ä¸å»ºè­°ç›´æ¥è‡¨åºŠæ‡‰ç”¨**ï¼ŒåŸå› å¦‚ä¸‹ï¼š
1. ç¼ºä¹å°ˆé–€çš„è‡¨åºŠè©¦é©—è­‰æ“š
2. ç¾æœ‰æ›´æœ‰æ•ˆçš„è‚ºé«˜å£“å°ˆç”¨è—¥ç‰©
3. Felodipine å°è‚ºè¡€ç®¡çš„é¸æ“‡æ€§ä¸å¦‚å…¶ä»–è—¥ç‰©
4. æƒ¡æ€§é«˜è¡€å£“é€šå¸¸éœ€è¦æ›´ç©æ¥µçš„ä»‹å…¥æ²»ç™‚

### å»ºè­°è¡Œå‹•
- [ ] å°æ–¼æƒ¡æ€§é«˜è¡€å£“ï¼Œå¯ä½¿ç”¨å…¶ä»–æ›´å¿«é€Ÿä½œç”¨çš„é™å£“è—¥
- [ ] è‚ºé«˜å£“æ‡‰ç”±å°ˆç§‘é†«å¸«ä½¿ç”¨æ ¸å‡†çš„å°ˆé–€è—¥ç‰©æ²»ç™‚
- [ ] ä¸å»ºè­°å°‡ felodipine ä½œç‚ºé€™äº›é©æ‡‰ç—‡çš„ä¸€ç·šé¸æ“‡

### ç‰¹æ®Šæƒ…æ³è€ƒé‡
åœ¨ç„¡æ³•å–å¾—å°ˆé–€è‚ºé«˜å£“è—¥ç‰©çš„ç·Šæ€¥æƒ…æ³ä¸‹ï¼Œéˆ£é›¢å­é€šé“é˜»æ–·åŠ‘å¯èƒ½æ˜¯ä¸€å€‹å‚™é¸ï¼Œä½†éœ€è¦å¯†åˆ‡ç›£æ¸¬ã€‚

### é¢¨éšªç­‰ç´š
**é«˜é¢¨éšª** - ä¸å»ºè­°è¶…é©æ‡‰ç—‡ä½¿ç”¨æ–¼è‚ºé«˜å£“ï¼›æƒ¡æ€§é«˜è¡€å£“éœ€è¦æ›´ç©æ¥µçš„æ²»ç™‚ç­–ç•¥

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€TFDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Lidocaine]({{ "/drugs/lidocaine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Fenoterol]({{ "/drugs/fenoterol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Felodipineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/felodipine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_felodipine,
  title = {Felodipineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/felodipine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
